Pharmaceutical composition as well as preparation method and application thereof

By preparing a pharmaceutical composition containing compound (I) and specific excipients, using CD81 to regulate the metabolism function of immune cells, the problems of limited types and poor efficacy of existing asthma treatment drugs are solved, providing high stability and suitable for non-invasiveness The treatment plan for sexual administration is suitable for patients with refractory asthma.

CN118987166APending Publication Date: 2024-11-22SHANGHAI INST OF PHARMA IND CO LTD +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411072216.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

There are limited types of asthma treatment drugs, especially for patients with refractory asthma, the application population of targeted therapeutic drugs is limited, the administration compliance is poor and expensive, and the efficacy of simply blocking cytokines is not obvious.

Method used

Provided is a pharmaceutical composition comprising Compound (I) or a pharmaceutically acceptable salt, excipient, acid, inorganic salt and organic salt thereof, prepared into an inhalation solution by a specific pH value, cosolvent and amino acid ratio. Preparation or dry powder preparation, using CD81 to regulate the metabolism function of immune cells and exert anti-asthmatic airway inflammation.

Benefits of technology

The pharmaceutical composition has good stability and biological activity, is suitable for non-invasive drug delivery routes, is suitable for the treatment of allergic asthma, providing new targets and better therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987166A_ABST
    Figure CN118987166A_ABST
Patent Text Reader

Abstract

The invention discloses a pharmaceutical composition as well as a preparation method and application thereof. Comprising the following components in parts by weight: 0.2-2 parts of a compound (I) or a pharmaceutically acceptable salt thereof, and pharmaceutic adjuvants, and the pharmaceutic adjuvants comprise 60-200 parts of an excipient and water; the excipient is selected from one or more of mannitol, maltose, fructose, lactose and glucose; the pH (Potential of Hydrogen) value of the pharmaceutical composition is 1.5 to 5.0. The pharmaceutical composition has good stability, and has good application prospects in preparation of drugs for preventing and / or treating respiratory system diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and in particular to a pharmaceutical composition, a preparation method thereof and an application thereof. Background Art

[0002] At present, there are more than 200 drugs for the treatment of asthma in the clinical and experimental stages in China. Its targets mainly include β2 receptors, glucocorticoid receptors, phosphodiesterase-4, genes in the leukotriene synthesis pathway, cytochrome P450 enzyme system, IL-4 / 5 receptors, etc. Although multiple targeted therapeutic drugs have been used in clinical practice, the first-line drugs for the treatment of mild and moderate asthma are still mainly glucocorticoids combined with classic control or relief drugs, supplemented by targeted therapeutic drugs. Especially for patients with refractory asthma, their medication is very limited. Targeted therapeutic drugs also have the characteristics of limited applicable groups, poor compliance with administration, and high prices. In view of the complexity of the pathogenesis of asthma, simply blocking a certain cytokine is not effective.

[0003] SP is a peptide drug used to treat allergic asthma. It is a brand-new compound molecule composed of seven amino acid residues. Its active structure is a peptide mimetic designed for CD81 based on the amino acid sequence of the HCV E2 region. The mimetic peptide was structurally modified and site-modified according to its pharmacokinetic characteristics, and finally SP with stable efficacy and long half-life was selected as a candidate drug molecule. The mechanism of its action was explored through technical means such as single-cell transcriptome sequencing and metabolomics analysis, proving that SP exerts its anti-asthmatic airway inflammation effect by targeting CD81 to regulate the metabolic function of immune cells. Thus, a peptide mimetic drug SP for the treatment of allergic asthma with a new target and new mechanism with good biological activity, high metabolic stability, and more suitable for non-invasive administration routes was found. Summary of the invention

[0004] The present invention aims to overcome the defect of limited types of pharmaceutical compositions for treating asthma in the prior art, and thus provides a pharmaceutical composition, a preparation method thereof and an application thereof. The pharmaceutical composition of the present invention has good stability and good application prospects.

[0005] The present invention provides a pharmaceutical composition A, which comprises the following components in parts by weight:

[0006] 0.2-2 parts of compound (I) or a pharmaceutically acceptable salt thereof,

[0007] and pharmaceutical excipients, the pharmaceutical excipients comprising 60-200 parts of excipients and water; the excipients are selected from one or more of mannitol, maltose, fructose, lactose and glucose; the pH value of the pharmaceutical composition is 1.5-5.0;

[0008]

[0009] In a certain embodiment, the compound (I) or a pharmaceutically acceptable salt thereof is 0.5 parts, 1 parts, 1.5 parts or 2 parts.

[0010] In a certain embodiment, the compound (I) or a pharmaceutically acceptable salt thereof is 0.5-1.5 parts.

[0011] In a certain embodiment, the pharmaceutical excipient further comprises an acid; the acid is selected from one or more of acetic acid, hydrochloric acid and phosphoric acid; preferably hydrochloric acid.

[0012] In one embodiment, the salt is trifluoroacetate.

[0013] In a certain embodiment, the pharmaceutical excipients further include inorganic salts and organic salts. The inorganic salt may be sodium chloride; the organic salt may be sodium trifluoroacetate.

[0014] In one embodiment, the pH value of the pharmaceutical composition is 3.0, 3.5, 4.0, 4.5 or 5.0.

[0015] In one embodiment, the pH value of the pharmaceutical composition is 3.0-3.5.

[0016] In a certain embodiment, the excipient is selected from one or more of mannitol, maltose, lactose and glucose; preferably mannitol or lactose.

[0017] In a certain embodiment, the content of the excipient is 100-180 parts; preferably 101.4 parts, 140 parts or 170 parts; more preferably 140 parts.

[0018] In a certain embodiment, the pharmaceutical composition further includes 0.5-7 parts of a solubilizing agent and / or 2-10 parts of an amino acid; the solubilizing agent is preferably 0.6-6 parts; for example, 1 part, 1.1 parts or 6 parts, and for example, 6 parts; the amino acid is 2 parts, 4 parts, 6 parts, 8 parts or 10 parts, for example, 2 parts.

[0019] In a certain embodiment, the cosolvent is DPTA, EDTA, polysorbate 80, poloxamer 188, Span 20 or polysorbate 80+EDTA; preferably polysorbate 80, poloxamer 188, Span 20 or polysorbate 80+EDTA; more preferably poloxamer 188.

[0020] In a certain embodiment, the amino acid is selected from one or more of lysine, methionine, histidine, glycine, glutamine, arginine and proline; preferably arginine or glutamine; more preferably arginine.

[0021] In a certain embodiment, the osmotic pressure ratio of the pharmaceutical composition is 0.9 to 1.3.

[0022] In a certain embodiment, the pharmaceutical composition further comprises water; the water may be water for injection.

[0023] In a certain embodiment, the pharmaceutical composition comprises any of the following embodiments or consists of the following embodiments:

[0024] (1) the compound (I) or a pharmaceutically acceptable salt thereof, the water and the excipient; the pH value is as described in any of the previous schemes;

[0025] (2) the compound (I) or a pharmaceutically acceptable salt thereof, the water, the excipient, the cosolvent and the amino acid; the pH value is as described in any of the previous embodiments; and

[0026] (3) the compound (I) or a pharmaceutically acceptable salt thereof, the water, the excipient and the amino acid; the pH value is as described in any of the previous embodiments;

[0027] Preferably,

[0028] (1) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of maltose, and water, pH 4.0;

[0029] (2) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of fructose, water, pH 4.0;

[0030] (3) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, water, pH 4.0;

[0031] (4) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of glucose, water, pH 4.0;

[0032] (5) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of polysorbate 20, and water, pH 4.0;

[0033] (6) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of polysorbate 80, and water, pH 4.0;

[0034] (7) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of poloxamer 188, and water, pH 4.0;

[0035] (8) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of Span 20, and water, pH 4.0;

[0036] (9) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of polysorbate + 0.1 part of EDTA, water, pH 4.0;

[0037] (10) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, water, pH 4.0;

[0038] (11) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of lysine, and water, pH 4.0;

[0039] (12) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of methionine, and water, pH 4.0;

[0040] (13) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, +4 parts of arginine, 6 parts of histidine, water, pH 4.0;

[0041] (14) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of glycine, water, pH 4.0;

[0042] (15) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of proline, and water, pH 4.0;

[0043] (16) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of glutamine, and water, pH 4.0;

[0044] (17) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 2 parts of arginine, water, pH 5.0;

[0045] (18) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 5.0;

[0046] (19) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 6 parts of arginine, water, pH 5.0;

[0047] (20) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 8 parts of arginine, water, pH 5.0;

[0048] (21) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 10 parts of arginine, water, pH 5.0;

[0049] (22) 0.5 parts of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, and water, pH 4.0;

[0050] (23) 1.5 parts of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, water, pH 4.0;

[0051] (24) 2 parts of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, and water, pH 4.0;

[0052] (25) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 3.0;

[0053] (26) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 3.5;

[0054] (27) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 4.0;

[0055] (28) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 4.5;

[0056] (29) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, 4 parts of arginine, water, pH 3.0;

[0057] (30) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, water, pH 3.0;

[0058] (31) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 170 parts of lactose, water, pH 3.0;

[0059] (32) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, and water, pH 3.0;

[0060] (33) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of glucose, water, pH 3.0;

[0061] Preferably,

[0062] (1) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, and water, pH 4.0;

[0063] (2) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, and water, pH 3.0;

[0064] (3) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, and water, pH 3.5;

[0065] (4) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, and water, pH 3.0;

[0066] Also preferably,

[0067] 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, water, pH 3.0.

[0068] In one embodiment of the present invention, the pharmaceutical composition A may be a solution preparation for inhalation.

[0069] In one embodiment, the concentration of the compound (I) or a pharmaceutically acceptable salt thereof is (0.1-1) mg / mL; for example, 0.25 mg / mL, 0.5 mg / mL, 0.75 mg / mL or 1 mg / mL; preferably (0.25-0.75) mg / mL.

[0070] The present invention provides a pharmaceutical composition B, which is obtained by freeze-drying the pharmaceutical composition A.

[0071] The present invention provides a pharmaceutical composition C, which comprises the following components in parts by weight:

[0072] 0.2-2 parts of compound (I) or a pharmaceutically acceptable salt thereof,

[0073] And a pharmaceutical excipient, the pharmaceutical excipient comprises 60-200 parts of an excipient, the pharmaceutical composition C is dissolved in water, when the concentration of the compound (I) or a pharmaceutically acceptable salt thereof is (0.1-1) mg / mL, the pH of the pharmaceutical composition C is 1.5-5.0; the compound (I) or a pharmaceutically acceptable salt thereof and the excipient are as described in any embodiment of the present invention; the pharmaceutical excipient is as described in any embodiment of the present invention, except that it does not contain water.

[0074] In one embodiment, the pharmaceutical composition C is a dry powder preparation, and for example, a lyophilized powder injection preparation.

[0075] In a certain embodiment, the pharmaceutical composition C is an inhalation preparation.

[0076] The present invention provides a pharmaceutical composition D, the raw materials of which include 0.2-2 parts of the compound (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient, wherein the pharmaceutical excipient includes a pH regulator, 60-200 parts of an excipient and water; the pH values ​​of the compound (I) or a pharmaceutically acceptable salt thereof, the excipient, the pharmaceutical excipient and the pharmaceutical composition are as described in any scheme of the present invention.

[0077] In a certain embodiment, the pH adjuster is an acid or "acid and base"; the acid is selected from one or more of acetic acid, hydrochloric acid and phosphoric acid; preferably hydrochloric acid; the base is sodium hydroxide; the hydrochloric acid can be 5 mol / L hydrochloric acid; the sodium hydroxide can be 1 mol / L sodium hydroxide.

[0078] The present invention provides a method for preparing a solution preparation, wherein a compound (I) or a pharmaceutically acceptable salt thereof is dissolved in the presence of an excipient, water and a pH regulator to prepare a solution preparation; the excipient, the water, the pH regulator and the compound (I) or a pharmaceutically acceptable salt thereof are as described in any embodiment of the present invention.

[0079] The invention provides a method for preparing a solid preparation. The solution preparation is subjected to canning, semi-plugging, freeze drying, plugging, capping and packaging to prepare the solid preparation.

[0080] The present invention provides a pharmaceutical composition, which is the preparation method of the solution preparation as described above or the product prepared by the preparation method of the solution preparation as described above.

[0081] In the present invention, 0.5 mg / mL of compound (I) or a pharmaceutically acceptable salt thereof is considered as 1 part.

[0082] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0083] The reagents and raw materials used in the present invention are commercially available.

[0084] The positive progress of the present invention is that: the present invention discloses a pharmaceutical composition, a preparation method thereof and an application thereof. The pharmaceutical composition has good stability and has good application prospects in the preparation of drugs for preventing and / or treating respiratory diseases. DETAILED DESCRIPTION

[0085] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples.

[0086] The experimental methods in the following examples without specifying specific conditions were carried out according to conventional methods and conditions, or selected according to the product instructions.

[0087]

[0088] Composition composition:

[0089]

[0090] Preparation method:

[0091] Weigh mannitol and arginine and place them in a preparation tank, add a certain amount of water for injection, and dissolve until completely clear. Use 5mol / L hydrochloric acid-water solution to adjust the pH of the solution to 2.5 and stir evenly. Weigh the SP raw material, slowly add it to the above solution, and stir continuously until it is completely dissolved. Use 1mol / L sodium hydroxide-water solution to adjust the pH of the solution to 3.5 and stir evenly. Add water for injection and weigh it to 1ml, stir evenly, and fine-tune the final solution pH to 3.5. Filter the prepared solution through a 0.22μm PVDF microporous filter membrane to obtain the final solution, and obtain the final solution preparation after filling, plugging and capping.

[0092] For the composition to be freeze-dried, the present invention obtains the final solution according to the above preparation method, and then goes through the steps of filling, semi-plugging, freeze drying, plugging, capping and packaging to obtain the final freeze-dried powder injection preparation.

[0093] The pharmaceutical preparations involved in the present invention have all been subjected to microbial and endotoxin control on the materials, apparatuses, packaging materials, etc. used therein, and the prepared composition solution is finely filtered, and then the solution to be filled is obtained by terminal sterilization filtration. The materials in the entire process are not sterilized at high temperatures, which avoids the risk of high temperature-generated degradation impurities and improves the stability of the drug; in addition, the solution is freeze-dried to obtain a final pharmaceutical preparation with an extremely low moisture content (≤5%), and is stored in a dark place at 2°C to 8°C, which is beneficial to the storage stability of the preparation.

[0094] The following Examples 1-8 were prepared by a method similar to the above-mentioned preparation method.

[0095] Example 1 Investigation of excipient types in the composition

[0096] The composition contains SP raw material (0.5 mg / ml), pH regulator (appropriate amount of hydrochloric acid or sodium hydroxide), and excipients. The excipient can be selected from maltose, trehalose, fructose, sucrose, lactose, glucose, sorbitol, or no excipient is added. The amount of excipient added is 5% (w / v, g / mL), and the final pH of the solution is 4.0. The composition solution is tested at different temperatures, light, and repeated freeze-thaw at -20°C.

[0097] Table 1 Stability test results under different temperature and light conditions - 5 days

[0098]

[0099]

[0100] Table 2 Stability test results under different temperature and light conditions - 10 days

[0101]

[0102]

[0103] Table 3 Results of repeated freeze-thaw test

[0104]

[0105]

[0106] The data results show that under light conditions, the stability of the solution in the absence of trehalose, sucrose, sorbitol and excipients is poor. The repeated freeze-thaw test proves that lactose performs best.

[0107] Example 2 In the investigation test on the cosolvent involved in the present invention, a series of compositions were compared to show the stability of the compositions under different conditions when polysorbate 20 (0.05%, W / V), polysorbate 80 (0.05%, W / V), poloxamer 188 (0.3%, W / V), Span 20 (0.05%, W / V), and polysorbate 80+EDTA (0.05% / 0.005%, W / V) were added. The raw materials of the series of compositions are SP raw materials (0.5mg / ml), excipients (lactose 5%, W / V), pH regulators (5mol / L hydrochloric acid or 1mol / L sodium hydroxide) and amino acids (arginine 2mg / ml) or the cosolvent is missing, and the final pH of the solution is 4.0.

[0108] Table 4 Information on the addition of cosolvents in the formulation

[0109]

[0110] Note: In the process of preparing the solution, precipitation occurred in the solution of test group 4, so no subsequent investigation was performed.

[0111] Table 5 Cosolvent Investigation Test Results - 10 Days

[0112]

[0113]

[0114] Table 6 Solvent investigation test results - 40 days

[0115]

[0116]

[0117] Table 7 Solvent inspection test results - February

[0118]

[0119] Table 8 Solvent inspection - repeated freeze-thaw test results

[0120]

[0121]

[0122] The test data showed that compared with the test group 6 without adding a solvent, the compositions with added solvents had no significant difference in appearance, related substances, and content determination values. 340 From the measured values, the experimental group 3 with the addition of P188 has a slight advantage over the other groups. The results of the repeated freeze-thaw test showed that the solution of the experimental group with the addition of polysorbate 20 and P188 was clear and transparent in the fourth cycle, while the solutions of the other groups were precipitated; in the fifth cycle, only the solution of the experimental group with the addition of P188 was clear and transparent. This suggests that P188 has a potential solubilizing effect in the composition, which helps to improve the stability of the solution.

[0123] Example 3 In the investigation test on amino acid additives involved in the present invention, a series of compositions were compared to compare the stability performance of a series of compositions with added lysine, methionine, histidine, glycine, glutamine, and proline under different conditions. The series of compositions contain SP (0.5 mg / ml), excipient (lactose 5%, W / V), pH adjuster (5 mol / L hydrochloric acid or 1 mol / L sodium hydroxide), arginine 2 mg / ml and one of the amino acids or the amino acid is missing, and the pH of the composition solution is 4.0.

[0124] Table 9 Information on amino acid addition in the composition

[0125]

[0126]

[0127] Table 10 Results of amino acid addition test - 10 days

[0128]

[0129] Table 11 Results of amino acid addition test - 40 days

[0130]

[0131]

[0132] Table 12 Results of amino acid addition test - February

[0133]

[0134] The test data showed that after 10 days of illumination, precipitation occurred in the composition samples of the amino acid addition test group, while the composition solution without amino acid addition was clear and transparent, indicating that there was a potential risk of amino acid precipitation under illumination conditions, while no precipitation occurred in the composition solutions of each group under other conditions, indicating that illumination was not conducive to the storage of the composition. Under 40°C conditions, the data showed that the deamidation impurity (RRT1.25) in the test group with Gln addition was significantly lower than that in the other test groups, indicating that the addition of Gln can reduce the rate of increase of deamidation impurities. The remaining test groups had no obvious advantages over test group 7.

[0135] Example 4 The present invention has an investigation involving the amount of amino acid arginine added to the composition, and the stability of each composition at different addition amounts was investigated. The addition amount gradient investigated includes 1mg / ml, 2mg / ml, 3mg / ml, 4mg / ml, and 5mg / ml. This group of compositions includes SP raw material (0.5mg / ml), excipient (mannitol 5.07%, W / V), pH adjuster (5mol / L hydrochloric acid or 1mol / L sodium hydroxide), and arginine. The final pH of the solution was adjusted to 5.0. Different composition samples were placed under different conditions for stability investigation. The specific results are shown in the table.

[0136] Table 13 Arginine addition test results - 7 days

[0137]

[0138] Table 14 Arginine addition test results - 15 days

[0139]

[0140]

[0141] The test data showed that arginine had little effect on the impurities, related substances and appearance changes of SP preparations, and mainly affected the OD of SP. 340 The measured value, that is, the effect on the aggregation of SP, when the addition amount is 1 mg / ml, OD 340 The measured value of was significantly higher than that of other groups of samples, and the differences among other groups were not significant. Therefore, the amount of arginine added can be 2mg / ml to 5mg / ml.

[0142] Example 5 The present invention explores the concentration of SP raw materials in the composition and examines the stability of each composition solution at different SP concentrations. This group of compositions includes SP raw materials, excipients (lactose 5%, W / V), amino acids (arginine 2mg / ml), pH adjusters (5mol / L hydrochloric acid or 1mol / L sodium hydroxide), and the final pH of the solution is adjusted to 4.0. The concentrations of the raw materials include: 0.25mg / ml, 0.5mg / ml, 0.75mg / ml, 1.0mg / ml, 1.25mg / ml, 1.5mg / ml, 2.0mg / ml, and 3mg / ml. This group of compositions uses pH value as a pressure condition, and is placed under different conditions for stability inspection, and the optimal SP concentration range is preferably selected.

[0143] Table 15 SP concentration investigation test results

[0144]

[0145] The experimental phenomena suggest that under low temperature conditions, the composition has the risk of precipitation. At the same SP concentration, the lower the temperature, the easier it is to precipitate. SP is a polypeptide protein drug. According to the physical and chemical properties of SP, the drug needs to be stored at low temperatures. Under refrigerated conditions, the lower the concentration, the lower the probability of precipitation. Therefore, it is necessary to adjust the SP concentration according to the conditions of different compositions. In addition, this study also placed a composition with an SP concentration of 0.5 mg / ml (the final solution pH of this group of compositions was 3.5) at 4°C for 24 months. No opalescence or precipitation occurred, and the stability was good. Therefore, the composition as the final preparation is best with an SP concentration of 0.5 mg / ml and a pH of 3.5 or less.

[0146] Example 6 The present invention explores the pH of the composition solution and examines the stability of each composition under different pH conditions. The composition contains SP raw material (0.5 mg / ml), excipient (mannitol 5.07%, W / V), amino acid (arginine 2 mg / ml) and pH regulator (5 mol / L hydrochloric acid or 1 mol / L sodium hydroxide). The pH inspection points of the solution include: 3.0, 3.5, 4.0, 4.5, 5.0. The stability of each composition was investigated under different conditions of light, 40°C, 25°C and 4°C.

[0147] Table 16 Composition solution pH investigation test results - 7 days

[0148]

[0149] Table 17 Composition solution pH investigation test results - 20 days

[0150]

[0151]

[0152] Table 18 Composition solution pH investigation test results - 1 month

[0153]

[0154]

[0155] The test results show that during the sample placement process, when placed under light conditions for 1 month, precipitation occurred in all samples except the composition with a pH of 3.0. When placed at 25°C and 4°C for 1 month, the sample groups with pH values ​​of 3.0 and 3.5 were clear and transparent, while precipitation occurred in the other sample groups; the growth rate of related substances at 25°C was significantly higher than that at 4°C. High temperature of 40°C accelerated the degradation of each group of samples, and the related substances increased significantly, while the content of active ingredients decreased significantly. 340 The measured values ​​have no obvious correlation. Therefore, it is beneficial to store the composition at a pH between 3.0 and 3.5 under the conditions of being protected from light and 4°C.

[0156] Example 7 The present invention also relates to a comparative study on SP solution preparation and freeze-dried powder injection preparation. The components in the composition are explored. According to the different composition conditions in the table, the intermediate solution is prepared, and each group takes out part of the solution for packaging and freeze-drying. The remaining solution compositions of each group (Group I) and the compositions after freeze-drying (Group P) are placed under different conditions for stability investigation. The specific implementation is shown in the table.

[0157] Table 19 Composition of the composition

[0158]

[0159] Table 20 Freeze-drying process

[0160] Freeze drying stage Temperature / ℃ Change time / min Maintaining time / min Vacuum / mbar Loading -5 15 40 / Pre-freeze -40 30 300 / One-time drying -20 120 1800 0.15 Secondary drying 25 120 300 0

[0161] Table 21 Comparative test results of solution preparation and lyophilized preparation - 10 days

[0162]

[0163]

[0164] Table 22 Comparative test results of solution preparation and lyophilized preparation - 1 month

[0165]

[0166] Table 23 Comparative test results of solution preparation and lyophilized preparation - February

[0167]

[0168] The test data showed that under the same conditions, the impurities at RRT0.95 and RRT1.25 in the freeze-dried preparation composition increased more slowly. After being placed at 40°C for 2 months, the main peak purity of the freeze-dried preparation was significantly higher than that of the solution preparation. This suggests that the freeze-dried preparation has higher stability. 340 The measured values ​​showed no significant differences between the groups when the samples were stored for 2 months.

[0169] Example 8 The present invention also relates to a long-term test investigation on lactose, mannitol and glucose as components of the composition. The test sample investigation involved in this embodiment is placed at 2-8°C. Samples are taken and tested at 0 month, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months respectively. The specific composition and implementation of the composition are shown in the table.

[0170] Table 24 Composition formula information

[0171]

[0172]

[0173] Note: “ / ” means not tested, the same below.

[0174] Table 25 Long-term stability study results - glucose prescription

[0175]

[0176] Table 26 Long-term stability study results - Mannitol prescription

[0177]

[0178] Table 27 Long-term stability study results - lactose formulation

[0179]

[0180]

[0181] Conclusion: The above table data show that the three different compositions show obvious differences when placed at 2-8°C for a long time. The glucose prescription has white precipitation after 3 months, the mannitol prescription has white precipitation after 6 months, and the lactose prescription is still clear and transparent after 24 months, and the relevant substances are controllable, and the content, pH and sterility are all within the control range. It can be concluded that the lactose prescription has obvious advantages in developing the final preparation.

[0182] According to the contents disclosed in the present invention, although the compositions and methods of the present invention are described according to preferred embodiments, it is apparent to those skilled in the art that the compositions and / or methods described herein and the steps or sequence of steps of the methods may be modified without departing from the concept, spirit and scope of the present invention.

[0183] The contents mentioned in the above embodiments are not limitations of the present invention. Without departing from the concept of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms also belong to the protection scope of the present invention.

Claims

1. A pharmaceutical composition A, characterized in that: It contains the following components in parts by weight: 0.2-2 parts of compound (I) or a pharmaceutically acceptable salt thereof, and pharmaceutical excipients, the pharmaceutical excipients comprising 60-200 parts of excipients and water; the excipients are selected from one or more of mannitol, maltose, fructose, lactose and glucose; the pH value of the pharmaceutical composition is 1.5-5.0; 2. The pharmaceutical composition A according to claim 1, characterized in that: It meets one or more of the following conditions; (1) 0.5 parts, 1 parts, 1.5 parts or 2 parts of the compound (I) or a pharmaceutically acceptable salt thereof; (2) 0.5-1.5 parts of the compound (I) or a pharmaceutically acceptable salt thereof; (3) The pharmaceutical excipient further comprises an acid; the acid is selected from one or more of acetic acid, hydrochloric acid and phosphoric acid; preferably hydrochloric acid; (4) The salt is trifluoroacetate; (5) The pharmaceutical excipients also include inorganic salts and organic salts. The inorganic salt may be sodium chloride; the organic salt may be sodium trifluoroacetate; (6) The pH value of the pharmaceutical composition is 3.0, 3.5, 4.0, 4.5 or 5.0; (7) The pH value of the pharmaceutical composition is 3.0-3.5; (8) The excipient is selected from one or more of mannitol, maltose, lactose and glucose; preferably mannitol or lactose; (9) The content of the excipient is 100-180 parts; preferably 101.4 parts, 140 parts or 170 parts; more preferably 140 parts; (10) The pharmaceutical composition further comprises 0.5-7 parts of a cosolvent and / or 2-10 parts of an amino acid; the cosolvent is preferably 0.6-6 parts; for example, 1 part, 1.1 parts or 6 parts, and for example, 6 parts; the amino acid is 2 parts, 4 parts, 6 parts, 8 parts or 10 parts, for example, 2 parts; (11) The cosolvent is DPTA, EDTA, polysorbate 80, poloxamer 188, Span 20 or polysorbate 80+EDTA; preferably polysorbate 80, poloxamer 188, Span 20 or polysorbate 80+EDTA; more preferably poloxamer 188; (12) The amino acid is selected from one or more of lysine, methionine, histidine, glycine, glutamine, arginine and proline; preferably arginine or glutamine; more preferably arginine; (13) The osmotic pressure ratio of the pharmaceutical composition is 0.9 to 1.3; and (14) The pharmaceutical composition further comprises water; the water may be water for injection.

3. The pharmaceutical composition A as claimed in claim 1 or 2, characterized in that: The pharmaceutical composition comprises any of the following or consists of the following: (1) the compound (I) or a pharmaceutically acceptable salt thereof, the water and the excipient; the pH value; (2) the compound (I) or a pharmaceutically acceptable salt thereof, the water, the excipient, the cosolvent and the amino acid; the pH value; and (3) the compound (I) or a pharmaceutically acceptable salt thereof, the water, the excipient and the amino acid; the pH value; Preferably, (1) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of maltose, and water, pH 4.0; (2) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of fructose, water, pH 4.0; (3) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, water, pH 4.0; (4) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of glucose, water, pH 4.0; (5) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of polysorbate 20, and water, pH 4.0; (6) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of polysorbate 80, and water, pH 4.0; (7) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of poloxamer 188, and water, pH 4.0; (8) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of Span 20, and water, pH 4.0; (9) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 1 part of polysorbate + 0.1 part of EDTA, water, pH 4.0; (10) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, water, pH 4.0; (11) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of lysine, and water, pH 4.0; (12) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of methionine, and water, pH 4.0; (13) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, +4 parts of arginine, 6 parts of histidine, water, pH 4.0; (14) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of glycine, water, pH 4.0; (15) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of proline, and water, pH 4.0; (16) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, 6 parts of glutamine, and water, pH 4.0; (17) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 2 parts of arginine, water, pH 5.0; (18) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 5.0; (19) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 6 parts of arginine, water, pH 5.0; (20) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 8 parts of arginine, water, pH 5.0; (21) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 10 parts of arginine, water, pH 5.0; (22) 0.5 parts of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, and water, pH 4.0; (23) 1.5 parts of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, water, pH 4.0; (24) 2 parts of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, 4 parts of arginine, and water, pH 4.0; (25) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 3.0; (26) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 3.5; (27) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 4.0; (28) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, water, pH 4.5; (29) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, 4 parts of arginine, water, pH 3.0; (30) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, water, pH 3.0; (31) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 170 parts of lactose, water, pH 3.0; (32) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, water, pH 3.0; (33) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of glucose, water, pH 3.0; Preferably, (1) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 100 parts of lactose, and water, pH 4.0; (2) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, and water, pH 3.0; (3) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 101.4 parts of mannitol, 4 parts of arginine, and water, pH 3.5; (4) 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, and water, pH 3.0; Also preferably, 1 part of compound (I) or a pharmaceutically acceptable salt thereof, 140 parts of lactose, water, pH 3.

0.

4. The pharmaceutical composition A according to claim 1, characterized in that: It meets one or both of the following conditions; (1) The pharmaceutical composition A may be a solution preparation for inhalation; and (2) The concentration of the compound (I) or a pharmaceutically acceptable salt thereof is (0.1-1) mg / mL; for example, 0.25 mg / mL, 0.5 mg / mL, 0.75 mg / mL or 1 mg / mL; preferably (0.25-0.75) mg / mL.

5. A pharmaceutical composition B, characterized in that: It is obtained by freeze-drying the pharmaceutical composition A as described in any one of claims 1 to 4.

6. A pharmaceutical composition C, characterized in that: It contains the following components in parts by weight: 0.2-2 parts of compound (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical excipient, wherein the pharmaceutical excipient comprises 60-200 parts of an excipient, and when the pharmaceutical composition C is dissolved in water and the concentration of the compound (I) or a pharmaceutically acceptable salt thereof is (0.1-1) mg / mL, the pH of the pharmaceutical composition C is 1.5-5.0; The compound (I) or a pharmaceutically acceptable salt thereof and the excipient are as described in any one of claims 1 to 4; The pharmaceutical excipient is as described in any one of claims 1 to 4, except that it does not contain water.

7. The pharmaceutical composition C according to claim 6, characterized in that It meets one or more of the following conditions: (1) The pharmaceutical composition C is a dry powder preparation, and for example, a lyophilized powder injection preparation; (2) The pharmaceutical composition C is an inhalation preparation.

8. A pharmaceutical composition D, characterized in that: The raw material comprises 0.2-2 parts of the compound (I) or a pharmaceutically acceptable salt thereof, and pharmaceutical excipients, the pharmaceutical excipients comprising a pH regulator, 60-200 parts of excipients and water; The pH value of the compound (I) or a pharmaceutically acceptable salt thereof, the excipient, the pharmaceutical adjuvant and the pharmaceutical composition is as described in any one of claims 1 to 4.

9. The pharmaceutical composition D according to claim 8, characterized in that The pH regulator is an acid or "acid and base"; the acid is selected from one or more of acetic acid, hydrochloric acid and phosphoric acid; preferably hydrochloric acid; the base is sodium hydroxide; the hydrochloric acid can be 5 mol / L hydrochloric acid; the sodium hydroxide can be 1 mol / L sodium hydroxide.

10. A method for preparing a solution preparation, characterized in that: In the presence of an excipient, water and a pH regulator, compound (I) or a pharmaceutically acceptable salt thereof is dissolved to prepare a solution preparation; the excipient, the water, the pH regulator and the compound (I) or a pharmaceutically acceptable salt thereof are as described in any one of claims 1 to 4.

11. A method for preparing a solid preparation, characterized in that: The solution preparation as claimed in claim 10 is canned, semi-stoppered, freeze-dried, stoppered, capped and packaged to prepare a solid preparation.

12. A pharmaceutical composition, characterized in that The pharmaceutical composition is the method for preparing the solution preparation according to claim 10 or the product prepared by the method for preparing the solution preparation according to claim 10.

Citation Information

Cited By

  • Pharmaceutical composition, preparation method therefor and use thereof

    WO2026031421A1